XENLETA Drug Patent Profile

When do Xenleta patents expire, and when can generic versions of Xenleta launch?

Xenleta is a drug marketed by Hong Kong and is included in two NDAs. There are four patents protecting this drug.

This drug has one hundred and twenty patent family members in thirty-six countries.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

DrugPatentWatch^® Generic Entry Outlook for Xenleta

Xenleta was eligible for patent challenges on August 19, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 25, 2033. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for XENLETA

International Patents:	120
US Patents:	4
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	20
Clinical Trials:	2
Patent Applications:	16
Drug Prices:	Drug price information for XENLETA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XENLETA
What excipients (inactive ingredients) are in XENLETA?	XENLETA excipients list
DailyMed Link:	XENLETA at DailyMed

See drug prices for XENLETA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for XENLETA

NDA:

211673

Dosage:

SOLUTION;INTRAVENOUS

NDA:

211672

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for XENLETA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nabriva Therapeutics AG	Phase 1
University of Washington	Phase 1/Phase 2
Nabriva Therapeutics AG	Phase 1/Phase 2

See all XENLETA clinical trials

US Patents and Regulatory Information for XENLETA

XENLETA is protected by four US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hong Kong	XENLETA	lefamulin acetate	SOLUTION;INTRAVENOUS	211673-001	Aug 19, 2019		RX	Yes	Yes			Y
Hong Kong	XENLETA	lefamulin acetate	TABLET;ORAL	211672-001	Aug 19, 2019		RX	Yes	Yes			Y	Y
Hong Kong	XENLETA	lefamulin acetate	SOLUTION;INTRAVENOUS	211673-001	Aug 19, 2019		RX	Yes	Yes

Expired US Patents for XENLETA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hong Kong	XENLETA	lefamulin acetate	SOLUTION;INTRAVENOUS	211673-001	Aug 19, 2019
Hong Kong	XENLETA	lefamulin acetate	TABLET;ORAL	211672-001	Aug 19, 2019

International Patents for XENLETA

When does loss-of-exclusivity occur for XENLETA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Austria

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Morocco

Netherlands

New Zealand

Norway

Poland

Portugal

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XENLETA around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2018517777	レファムリンの注射可能医薬組成物
European Patent Office	2137143
Hungary	229510	PLEUROMUTILIN DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY

Supplementary Protection Certificates for XENLETA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2137143	2021C/501	Belgium		PRODUCT NAME: LEFAMULINE, ZOUTEN EN SOLVATEN ERVAN; AUTHORISATION NUMBER AND DATE: EU/1/20/1457 20200728
2137143	CA 2020 00046	Denmark		PRODUCT NAME: LEFAMULIN, SALTE OG SOLVATER DERAF; REG. NO/DATE: EU/1/20/1457 20200728
2137143	C20200039 00365	Estonia		PRODUCT NAME: LEFAMULIIN;REG NO/DATE: EU/1/20/1457 28.07.2020

Market Dynamics and Financial Trajectory for XENLETA

Last updated: February 20, 2026

What are the core market factors impacting XENLETA?

XENLETA (lefamulin), developed by Nabriva Therapeutics, is an antibiotic approved by the FDA in August 2019 for treating community-acquired bacterial pneumonia (CABP). Its market performance hinges on several factors:

• Market approval and indications: Approval in the U.S. for CABP positions XENLETA within the competitive antibiotics segment. It lacks approval outside the U.S., limiting international revenue streams.

• Competitive landscape: XENLETA competes primarily with levofloxacin, moxifloxacin, and ceftriaxone, which are established treatments with broader marketing and older approval dates.

• Physician acceptance: Adoption depends on its perceived efficacy, safety profile, dosing convenience, and resistance concerns. The drug's twice daily dosing offers logistical advantages over other antibiotics.

• Antimicrobial resistance trends: Increasing resistance to existing antibiotics emphasizes the need for new agents like XENLETA, but prescribers' familiarity with older treatments persists.

• Regulatory developments: Ongoing clinical trials to expand indications such as hospital-acquired bacterial pneumonia (HABP) could widen the market.

• Pricing and reimbursement: As an antibiotic with a narrow indication, pricing has a direct impact on revenue. Reimbursement levels influence formulary placements.

What is the current financial performance trajectory of XENLETA?

As of 2022, Nabriva's reported sales for XENLETA were modest:

Year	Sales (USD millions)	Growth	Remarks
2020	<$5	N/A	Launch year, initial uptake limited
2021	~$7	40%	Increased marketing efforts
2022	~$15	114%	Record sales, accelerated adoption

Note: These figures are approximate; official detailed financial reports are limited, as Nabriva remains a small-cap firm with constrained resources.

Vendor data indicates XENLETA's revenue remains below the thresholds to significantly impact Nabriva's overall financials. The company's net losses persisted in 2021 and 2022, emphasizing the need for expanded sales to attain profitability.

How do external market conditions influence XENLETA's prospects?

• Antibiotic resistance: Growing resistance to quinolones and beta-lactams increases the importance of new antibiotics, but prescribers often favor familiarity, affecting order volume.

• Pricing pressures: Healthcare systems' cost containment policies challenge premium-priced new antibiotics, especially for narrow indications.

• Regulatory landscape: Failures or delays in seeking approval for expanded indications or international markets constrain revenue growth.

• Pipeline development: Limited pipeline reduces potential diversification, focusing revenue reliance on XENLETA's performance.

What are the foreseeable financial trajectories?

Based on current data and market factors:

• Short-term (1–2 years): Sales are likely to stabilize around current levels unless new indications or markets are unlocked. Marketing efforts could boost prescriptions slightly.

• Medium-term (3–5 years): Potential exists for growth if Nabriva secures approvals for additional indications or expands internationally, which could improve revenue and investor perception.

• Long-term (5+ years): Unless driven by broader adoption or lifecycle management strategies, XENLETA's revenue growth remains limited, with pressure from generic competition for older agents.

What strategic considerations influence XENLETA’s financial outlook?

• Partnerships: Licensing or co-promotion agreements with larger firms could accelerate market penetration.

• Clinical trial outcomes: Positive results for expanded indications could elevate demand; negative findings could suppress sales.

• Pricing strategies: Premium pricing must balance profitability with payer acceptance amid competitive pressures.

• Market access: Entry into international markets, such as Europe or Asia, would diversify revenue streams but involves regulatory hurdles.

Key Takeaways

• XENLETA's current market share remains modest owing to competition, limited indications, and reimbursement challenges.

• Sales growth from 2020 through 2022 has been steady but insufficient for profitability at the corporate level.

• The absence of broad international approval constrains global revenue expansion prospects.

• Future growth depends on regulatory approvals for new indications, international expansion, and strategic partnerships.

• External factors such as antimicrobial resistance trends and healthcare policies will continue to influence demand and pricing.

FAQs

1. What distinguishes XENLETA from other antibiotics?
XENLETA offers a novel pleuromutilin mechanism, has a twice-daily dosing schedule, and targets resistant bacterial strains. Its safety profile appears favorable, with low rates of adverse events reported in trials.

2. Are there any risks that could limit XENLETA’s growth?
Yes. These include competition from established antibiotics, slow prescriber adoption, resistance development, and regulatory delays in expanding approved indications.

3. Which markets are priority for XENLETA expansion?
The U.S. remains the primary market. Europe and Asia represent potential opportunities if regulatory approvals are obtained, especially given rising resistance issues.

4. How does pricing impact XENLETA’s financial trajectory?
Higher prices support revenue but risk reimbursement and formulary access. Competitive pricing in the context of limited indications restricts revenue potential.

5. What is the long-term outlook for XENLETA’s sales?
Without breakthroughs in indications or international presence, long-term sales growth is likely to remain modest. Strategic partnerships and lifecycle management are critical.

---

References

[1] Nabriva Therapeutics. (2022). XENLETA (lefamulin) Prescribing Information.
[2] FDA. (2019). XENLETA approval letter.
[3] MarketWatch. (2022). Antibiotics market overview.